Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
暂无分享,去创建一个
Benoit Blanchet | Nicolas Dupin | F. Goldwasser | N. Dupin | M. White-Koning | E. Chatelut | B. Blanchet | A. Puszkiel | G. Noé | A. Thomas-Schoemann | M. Vidal | François Goldwasser | Etienne Chatelut | Mélanie White-Koning | Alicja Puszkiel | Nora Kramkimel | Audrey Thomas-Schoemann | Gaëlle Noé | Nicolas Chapuis | Michel Vidal | N. Chapuis | N. Kramkimel
[1] H. Drexler,et al. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. , 1998, Leukemia research.
[2] F. Liu,et al. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] J. Garcia,et al. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase‐3β , 2002 .
[4] S. Clarke,et al. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. , 2003, The Lancet. Oncology.
[5] Toshikazu Nakamura,et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. , 2004, Experimental hematology.
[6] Toshikazu Nakamura,et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1α, and stem cell factor , 2004 .
[7] I. S. Dunn,et al. Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression , 2006, Molecular Cancer Research.
[8] J. Blay,et al. Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors , 2006, Clinical Cancer Research.
[9] A. Birukova,et al. Magnitude-dependent effects of cyclic stretch on HGF- and VEGF-induced pulmonary endothelial remodeling and barrier regulation. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[10] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[11] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[12] B. Comin-Anduix,et al. The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.
[13] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[14] I. Wilhelm,et al. Transmigration of Melanoma Cells through the Blood-Brain Barrier: Role of Endothelial Tight Junctions and Melanoma-Released Serine Proteases , 2011, PloS one.
[15] J. Wilmott,et al. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.
[16] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[17] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[18] A. Giobbie-Hurder,et al. The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition , 2012, Clinical Cancer Research.
[19] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[20] M. Donia,et al. BRAF inhibition improves tumor recognition by the immune system , 2012, Oncoimmunology.
[21] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[22] France Mentré,et al. Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[23] R. Sullivan,et al. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.
[24] J. Sosman,et al. Impact of MET expression on outcome in BRAFV600E/K advanced melanoma , 2013, Histopathology.
[25] F. Goldwasser,et al. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[26] G. Freeman,et al. Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade , 2014, Cancer Immunology Research.
[27] Y. Shimada,et al. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer , 2014, British Journal of Cancer.
[28] M. Mihm,et al. Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors , 2013, Modern Pathology.
[29] A. Ribas,et al. The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics , 2014, Journal of clinical pharmacology.
[30] H. Yatsuhashi,et al. Hepatocyte growth factor enhances the barrier function in primary cultures of rat brain microvascular endothelial cells. , 2014, Microvascular research.
[31] J. Utikal,et al. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] F. Goldwasser,et al. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma , 2016, Targeted Oncology.
[33] C. Funck-Brentano,et al. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] G. Linette,et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. , 2015 .
[35] T. Graeber,et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma , 2015, Science Translational Medicine.
[36] R. Dummer,et al. A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma , 2015, Pharmacology research & perspectives.
[37] C. Lebbé,et al. Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] L. Chin,et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma , 2016, Oncoimmunology.